| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | $39.4M+63.4% | $24.1M-28.2% | $33.6M+88.6% | $17.8M+45.1% | $12.3M | $0 | $0-100.0% | $750K-57.7% | $1.8M |
| Cost of revenues | $74.6M-4.3% | $77.9M-7.0% | $83.8M-3.9% | $87.2M | — | — | — | $15.4M+0.9% | $15.2M |
| Research and development | $106.2M-2.4% | $108.8M+18.8% | $91.6M+22.9% | $74.6M-17.6% | $90.5M+19.1% | $76.0M+9.9% | $69.1M-22.5% | $89.2M+79.9% | $49.6M |
| Selling, general and administrative | $485.6M+51.0% | $321.6M-4.4% | $336.4M-10.8% | $377.2M+23.8% | $304.8M+51.9% | $200.7M+31.0% | $153.2M-0.9% | $154.7M+12.2% | $137.9M |
| Amortization of intangible assets | $89.5M+14.7% | $78.0M-5.4% | $82.4M-0.3% | $82.6M+175.5% | $30.0M+91.0% | $15.7M+203.2% | $5.2M-0.2% | $5.2M | — |
| Intangible asset impairment charges | $0 | $0-100.0% | $20.2M | $0 | $0 | — | — | — | — |
| Contingent consideration loss (gain) | $25.4M+516.0% | -$6.1M-302.8% | -$1.5M-197.5% | -$510K+92.2% | -$6.5M-443.7% | $1.9M | $0 | $0 | — |
| Total costs and expenses | $781.2M+34.7% | $580.2M-5.3% | $612.8M-1.3% | $621.1M+25.8% | $493.7M+42.4% | $346.7M+42.0% | $244.2M-7.7% | $264.5M+30.5% | $202.7M |
| Operating earnings (loss) | -$62.3M-176.3% | $81.7M+1649.9% | -$5.3M-111.4% | $46.1M-46.4% | $86.0M-50.5% | $173.7M+16.9% | $148.6M+2.9% | $144.4M+45.1% | $99.5M |
| Interest and other income, net | $13.3M-18.2% | $16.2M+55.0% | $10.5M-51.8% | $21.7M+105.2% | $10.6M-43.5% | $18.7M-13.5% | $21.6M+56.2% | $13.8M+1185.3% | $1.1M |
| Interest expense | $0 | $0+100.0% | -$2.4M+65.8% | -$7.1M+69.8% | -$23.4M+1.4% | -$23.8M-4.6% | -$22.7M-25.4% | -$18.1M-1055.0% | -$1.6M |
| Total other income (expense), net | $13.3M-18.2% | $16.2M+101.6% | $8.0M-45.0% | $14.6M | — | — | — | — | — |
| Earnings (loss) before income taxes | -$49.0M-150.1% | $97.9M+3434.5% | $2.8M-95.4% | $60.7M-17.0% | $73.2M-56.6% | $168.6M+14.3% | $147.5M+5.2% | $140.2M+39.3% | $100.6M |
| Income tax expense (benefit) | -$10.5M-143.7% | $24.0M+1552.1% | $1.5M+4440.6% | $32K-99.8% | $19.8M-52.6% | $41.7M+21.1% | $34.4M+18.0% | $29.2M-32.7% | $43.3M |
| Net earnings (loss) | -$38.5M-152.2% | $73.9M+5512.8% | $1.3M-97.8% | $60.7M+13.6% | $53.4M-57.9% | $127.0M+12.3% | $113.1M+1.9% | $111.0M+93.8% | $57.3M |
| Basic (in dollars per share) | -$680.00-150.7% | $1340.00+6600.0% | $20.00-98.2% | $1130.00+11.9% | $1010.00+41808.7% | $2.41+11.6% | $2.16+1.4% | $2.13+88.5% | $1.13 |
| Diluted (in dollars per share) | -$680.00-151.5% | $1320.00+6500.0% | $20.00-98.1% | $1040.00+6.1% | $980.00+41425.4% | $2.36+12.4% | $2.10+2.4% | $2.05+89.8% | $1.08 |
| Basic (in shares) | 56.45B+2.5% | 55.10B+1.0% | 54.54B+1.6% | 53.67B+1.1% | 53.10B+0.9% | 52.62B+0.4% | 52.41B+0.8% | 51.99B+2.4% | 50.76B |
| Diluted (in shares) | 56.45B+0.9% | 55.96B+0.8% | 55.51B-10.0% | 61.68B+13.5% | 54.36B+1.2% | 53.69B-0.2% | 53.82B-0.5% | 54.10B+1.5% | 53.30B |
| Net product sales | |||||||||
| Collaboration revenue (ZURZUVAE) | |||||||||
| Royalty, licensing, and other revenues | |||||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.